From: Does larch arabinogalactan enhance immune function? A review of mechanistic and clinical trials
Population analysed | FASa | PPa set | ||
---|---|---|---|---|
Groups | Placebo | AGa | Placebo | AGa |
Number of common cold episodes | 1.06 ± 0.85 | 0.83 ± 0.82 | 1.10 ± 0.85 | 0.85 ± 0.82 * |
Number of subjects affected by a cold episode | 72.4Â % | 58.4Â % * | 74.4Â % | 59.8Â % * |
Duration of common cold episodes | 8.3 ± 2.9 | 8.5 ± 2.8 | - | - |
Intensity of symptoms after 5 days, documented in CRFa | 8.5 ± 6.6 | 8.4 ± 6.8 | - | - |
Intensity of symptoms after 5 days, from subject diary | 5.85 ± 8.35 | 4.73 ± 8.08 | - | - |
Intensity of symptoms at start, documented in CRFa | 11.6 ± 6.3 | 13.3 ± 6.6 | - | - |
Intensity of symptoms at start, from subject diary | 11.5 ± 6.5 | 13.7 ± 6.9 * | - | - |